Vesper Bio announces positive Phase Ib/IIa topline results for lead candidate VES001 for frontotemporal degeneration

Phase Ib/IIa study found VES001, the first oral therapy being tested in FTD, led to >95% mean increase in progranulin levels in CSF, compared to baseline Topline results indicate VES001 normalises levels of progranulin in people who have a shortage of this vital protein for genetic...